Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy and Safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as Perioperative Chemotherapy Treatments for Resectable Gastric Cancer Patients

View ORCID ProfilePegah Farrokhi, Alireza Sadeghi, Mehran sharifi, View ORCID ProfilePayam Dadvand, View ORCID ProfileRachel Riechelmann, View ORCID ProfileAzadeh Moghaddas
doi: https://doi.org/10.1101/2021.01.26.21250550
Pegah Farrokhi
1Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pegah Farrokhi
Alireza Sadeghi
2Department of Internal Medicine-Hematology Section, Isfahan University of Medical Sciences, Isfahan, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mehran sharifi
2Department of Internal Medicine-Hematology Section, Isfahan University of Medical Sciences, Isfahan, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Payam Dadvand
3Barcelona Institute for Global Health, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Payam Dadvand
Rachel Riechelmann
4Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rachel Riechelmann
Azadeh Moghaddas
1Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Azadeh Moghaddas
  • For correspondence: moghaddas@pharm.mui.ac.ir
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose This study aimed to compare the efficacy and toxicity of perioperative chemotherapy regimens including ECF, DCF, FOLFOX, and FLOT to identify the most effective chemotherapy regimen with less toxicity.

Method This retrospective cohort study(2014-2021) was based on 152 eligible resectable gastric cancer patients who had received one of the perioperative chemotherapy regimens including ECF, DCF, FOLFOX, or FLOT, and followed for at least two years. The primary endpoint of this study was Overall Survival (OS), Progression-Free Survival (PFS), Overall Response Rate (ORR), and R0 resection. We also considered toxicity according to CTCAE (v.4.0) criteria as a secondary endpoint.

Results Of included patients, 32(21%), 51(33.7%), 37(24.3%), and 32(21%) had received ECF, DCF, FOLFOX and FLOT, respectively. After the median 30 months follow-up, overall survival was higher with the FLOT regimen in comparison with other regimens (hazard ratio [HR] = 0. 276). The median OS of the FLOT regimen was 39 months. Besides, the median OS was 28, 25, and 21 months for DCF, FOLOFX, and ECF regimens, respectively. Moreover, a median PFS of 24, 18, 17, and 14 months was observed for FLOT, DCF, FOLFOX, and ECF regimens, respectively (Log-rank <0.001). FLOT regimen showed 84. 4% ORR, was notably higher than other groups (p-value<0. 01).

Conclusions For resectable gastric cancer patients, the perioperative FLOT regimen led to a significant improvement in patients’ OS and PFS in comparison with ECF, DCF, and FOLFOX regimens. As such, the FLOT regimen could be considered the optimal option for managing resectable gastric cancer patients.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was part of an Iranian Pharm. D thesis that has been supported by Isfahan University of Medical Sciences (Grant number: 398162).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Ethics Committee of Isfahan University of Medical Sciences with the Iranian approval ID of IR.MUI.RESEARCH.REC.1398.167.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data are available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 02, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy and Safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as Perioperative Chemotherapy Treatments for Resectable Gastric Cancer Patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy and Safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as Perioperative Chemotherapy Treatments for Resectable Gastric Cancer Patients
Pegah Farrokhi, Alireza Sadeghi, Mehran sharifi, Payam Dadvand, Rachel Riechelmann, Azadeh Moghaddas
medRxiv 2021.01.26.21250550; doi: https://doi.org/10.1101/2021.01.26.21250550
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy and Safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as Perioperative Chemotherapy Treatments for Resectable Gastric Cancer Patients
Pegah Farrokhi, Alireza Sadeghi, Mehran sharifi, Payam Dadvand, Rachel Riechelmann, Azadeh Moghaddas
medRxiv 2021.01.26.21250550; doi: https://doi.org/10.1101/2021.01.26.21250550

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (160)
  • Allergy and Immunology (412)
  • Anesthesia (90)
  • Cardiovascular Medicine (855)
  • Dentistry and Oral Medicine (156)
  • Dermatology (97)
  • Emergency Medicine (247)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (392)
  • Epidemiology (8534)
  • Forensic Medicine (4)
  • Gastroenterology (381)
  • Genetic and Genomic Medicine (1739)
  • Geriatric Medicine (167)
  • Health Economics (370)
  • Health Informatics (1234)
  • Health Policy (618)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (369)
  • Infectious Diseases (except HIV/AIDS) (10271)
  • Intensive Care and Critical Care Medicine (552)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (210)
  • Neurology (1666)
  • Nursing (97)
  • Nutrition (247)
  • Obstetrics and Gynecology (325)
  • Occupational and Environmental Health (450)
  • Oncology (925)
  • Ophthalmology (262)
  • Orthopedics (100)
  • Otolaryngology (172)
  • Pain Medicine (110)
  • Palliative Medicine (40)
  • Pathology (249)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (246)
  • Primary Care Research (205)
  • Psychiatry and Clinical Psychology (1757)
  • Public and Global Health (3826)
  • Radiology and Imaging (622)
  • Rehabilitation Medicine and Physical Therapy (317)
  • Respiratory Medicine (518)
  • Rheumatology (207)
  • Sexual and Reproductive Health (164)
  • Sports Medicine (156)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (100)
  • Urology (74)